Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models

作者
Maryam Arshad,Abul Kalam Azad,Phoebe Yuen Ka Chan,Vasanthy Vigneswara,Katharina Feldinger,Siti Norasikin Mohd Nafi,Eloise Laporte-Maguire,Carmela De Santo,Jianmin Zuo,Abeer M. Shaaban,Anthony Kong
出处
期刊:British Journal of Cancer [Springer Nature]
卷期号:130 (12): 1990-2002 被引量:23
标识
DOI:10.1038/s41416-024-02665-z
摘要

BACKGROUND: Previous studies have suggested that patients with HER2-low breast cancers do not benefit from trastuzumab treatment although the reasons remain unclear. METHODS: We investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel of breast cancer cell lines and patient-derived organoids (PDOs) using biochemical methods and cell viability assays. RESULTS: Compared to sensitive HER2 over-expressing (IHC3 + ) breast cancer cells, increasing doses of trastuzumab could not achieve IC50 in MDA-MB-361 (IHC 2 + FISH + ) and MDA-MB-453 (IHC 2 + FISH-) cells which showed an intermediate response to trastuzumab. Trastuzumab treatment induced upregulation of HER ligand release, resulting in the activation of HER receptors in these cells, which could account for their trastuzumab insensitivity. Adding a dual ADAM10/17 inhibitor to inhibit the shedding of HER ligands in combination with trastuzumab only showed a modest decrease in the cell viability of HER2-low breast cancer cells and PDOs. However, the panHER inhibitor neratinib was an effective monotherapy in HER2-low breast cancer cells and PDOs, and showed additive effects when combined with trastuzumab. CONCLUSION: This study demonstrates that neratinib in combination with trastuzumab may be effective in a subset of HER2-low breast cancers although further validation is required in a larger panel of PDOs and in future clinical studies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Elsevier大王的应助被谦让的斓采纳,获得30
1秒前
1秒前
1秒前
2秒前
Hello的应助被健壮的化蛹采纳,获得20
3秒前
科研通AI6.2的应助被qqqqqqqqqq采纳,获得10
4秒前
不安的半梦完成签到,获得积分10
4秒前
饱满的雍发布了新的文献求助10
4秒前
秋风的应助被Xin采纳,获得150
4秒前
he发布了新的文献求助10
5秒前
6秒前
缪缪完成签到,获得积分10
6秒前
6秒前
华仔的应助被玉玉玉米采纳,获得10
6秒前
kk发布了新的文献求助10
6秒前
我是老大的应助被Spring采纳,获得10
6秒前
秋风的应助被谦让的斓采纳,获得10
7秒前
Seraphim发布了新的文献求助10
8秒前
赵玮佳完成签到 ,获得积分10
9秒前
秦博发布了新的文献求助10
10秒前
10秒前
XX发布了新的文献求助10
11秒前
11秒前
LI完成签到,获得积分10
12秒前
zr完成签到 ,获得积分10
12秒前
12秒前
xixixiziwei完成签到,获得积分10
12秒前
体贴苠的应助被含蓄雨柏采纳,获得10
13秒前
Jiaj完成签到 ,获得积分10
13秒前
14秒前
16秒前
qqqqqqqqqq完成签到,获得积分10
16秒前
小猛人发布了新的文献求助10
17秒前
17秒前
目渴完成签到 ,获得积分10
17秒前
丘比特的应助被Jeff采纳,获得10
18秒前
请问完成签到,获得积分10
18秒前
森林完成签到 ,获得积分10
19秒前
iceicefdtd发布了新的文献求助200
20秒前
刘刘pf发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194107
求助须知:如何正确求助?哪些是违规求助? 9580062
关于积分的说明 21869017
捐赠科研通 7793713
什么是DOI,文献DOI怎么找? 3437523
关于科研通互助平台的介绍 2560962
邀请新用户注册赠送积分活动 2484264